Dow Jones soars above 23,000. Is it too stretched? >>> READ MORE

4 Biotechnology Stocks to Sell Now

PGNX, ENZN, NYMX, PBTH slump in weekly rankings


For the current week, the overall ratings of four Biotechnology stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Progenics Pharmaceuticals‘s (NASDAQ:PGNX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum, Earnings Revisions, Equity, and Sales Growth, PGNX also gets F’s. For a full analysis of PGNX stock, visit Portfolio Grader.

Enzon Pharmaceuticals‘s (NASDAQ:ENZN) rating falls this week to a F (“strong sell”), down from last week’s D (“sell”). Enzon Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The stock gets F’s in Earnings Growth, Equity, and Sales Growth. The stock price has fallen 6.9% over the past month, worse than the 4.1% decrease the Nasdaq has seen over the same period of time. To get an in-depth look at ENZN, get Portfolio Grader’s complete analysis of ENZN stock.

The rating of Nymox Pharmaceutical (NASDAQ:NYMX) declines this week from a D to a F. Nymox Pharmaceutical is engaged in therapeutics in development for enlarged prostate, E. coli, Alzheimer’s disease and other indications and diagnostics for tobacco exposure, and other conditions. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. For a full analysis of NYMX stock, visit Portfolio Grader.

PROLOR Biotech (AMEX:PBTH) gets weaker ratings this week as last week’s C drops to a D. PROLOR Biotech offers treatment by using naturally occurring amino acid sequence to slow the removal of therapeutic proteins from the body without increasing toxicity or altering the overall biological activity. The stock also rates an F in Equity. For more information, get Portfolio Grader’s complete analysis of PBTH stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC